1. Academic Validation
  2. Exosomal ANXA2 facilitates ovarian cancer peritoneal metastasis by activating peritoneal mesothelial cells through binding with TLR2

Exosomal ANXA2 facilitates ovarian cancer peritoneal metastasis by activating peritoneal mesothelial cells through binding with TLR2

  • Cell Commun Signal. 2024 Dec 21;22(1):616. doi: 10.1186/s12964-024-01987-y.
Jingni Zhang # 1 Hongmei Liu # 1 Qiulei Wu 1 Tong Liu 1 Xiaoli Liu 1 Jing Cai 1 Xiaoqing Yi 1 Zehua Wang 2 Lingling Gao 3 4
Affiliations

Affiliations

  • 1 Departmentof Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • 2 Departmentof Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. zehuawang@hust.edu.cn.
  • 3 Departmentof Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. linglinggao@hust.edu.cn.
  • 4 Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. linglinggao@hust.edu.cn.
  • # Contributed equally.
Abstract

Background: Peritoneal dissemination of ovarian Cancer (OvCa) can be largely attributed to the formation of a metastatic microenvironment driven by tumoral exosomes. Here, we aimed to elucidate the mechanisms through which exosomal annexin A2 (AnxA2) derived from OvCa cells induces an HPMC phenotypic shift in favour of peritoneal metastasis.

Methods: Immunohistochemistry and orthotopic and intraperitoneal OvCa xenograft mouse models were used to clarify the relationship between tumour AnxA2 expression and peritoneal metastasis. Exosomes were isolated from OvCa cell lines via ultracentrifugation. Functional experiments on cell proliferation and motility, and western blot were performed to investigate the activation of HPMCs and its impact on tumour cell in vitro. High-throughput transcriptional Sequencing and rescue experiments in which AnxA2 Inhibitor (LCKLSL) or the Toll-like Receptor 2 (TLR2) inhibitor (C29) was used to co-culture the HPMCs with exosome were employed to identify the crucial Functional Molecules through which exosomal AnxA2 activates HPMCs. The impact of exosomal ANXA2-activated HPMCs on tumour progression was assessed via functional experiments.

Results: Primary OvCa samples with high AnxA2 expression exhibited a stronger tendency to metastasize to the abdominal cavity. Tumoral AnxA2 promoted OvCa peritoneal metastasis through the secretion of exosomes carrying AnxA2. ANXA2-loaded exosomes activated HPMCs through exosomal AnxA2 binding to TLR2, shifting the phenotype of HPMCs towards mesenchymal cells, increasing their migration and invasion capacities, and elevating the expression of lipocalin 2 (LCN2). High LCN2 expression in HPMCs promoted OvCa cell adhesion, proliferation, motility, and lipid metabolism reprogramming.

Conclusion: Exosomal AnxA2 secreted by tumour cells activates HPMCs and induces the expression of LCN2, which in turn promotes the peritoneal metastasis of OvCa.

Keywords

Annexin A2; Exosome; Human peritoneal mesothelial cell; Lipocalin 2; Ovarian cancer; Toll-like receptor 2.

Figures
Products